FF 
Principal Investigator/Program D'\TecioT{Lasi first, middle)'. _ 
Deisseroth, Albert. B, 
BIOGRAPHICAL SKETCH CVs 
Give the following information for the key personnel and consultants and collaborators. Begin with the principal 
investigator/program director. Photocopy this page for each person. 
NAME 
Albert B. Deisseroth, M.D., Ph.D. 
POSITION TITLE 
Professor and Chairman 
EDUCATIONfBeg/n with baccalaureate or other initial professional education, such as nursing, and include postdoaoral training.) 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
Univ. of Rochester, Rochester, NY 
A.B. 
1963 
Chemistry 
Univ. of Rochester School of Medicine, NY 
Ph.D. 
1968 
Biochemistry 
Univ. of Rochester School of Medicine, NY 
M.D. 
1970 
Medicine 
Intern & Junior Resident, Beth Israel Hospital, MA 
Resident 
1970-1972 
Internal Medicine 
Sidney Farber Center 
Fellow 
1975-1976 
Hematology /Oncology 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, 
experience, and honors. Key personnel include the principal investigator and any other individuals who participate in the scientific 
development or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees, 
but in some projects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the 
scientific development or execution of the project. Include present membership on any Federal Government public advisory committee. 
List, in chronological order, the titles, all authors, and complete references to all publications during the past three years and to 
representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES. 
POSITIONS HELD 
1970 - 1972 
1972 - 1974 
1974 - 1975 
1975 - 1976 
1976 - 1981 
1981 - 1987 
1987 - present 
1987 - present 
Intern and Resident, Beth Israel Hospital, Boston, MA 
Clinical Associate, NHLI, NIH 
Chief Resident Physican, NHLI, NIH 
Clinical Fellow, Hematology/Oncology, Children’s Hospital Medical Center, Boston, MA 
Head, Experimental Hematology Section, Pediatric Oncology Branch, NCI, NIH 
Chief, Hematology/Oncology Section, Department of Medicine, UCSF Service, San Francisco VA Medical 
Center, and Professor of Medicine, UCSF 
Prof, of Medicine and Chairman, Dept, of Hematology, U.T. M.D. Anderson Cancer Center, Houston, TX 
Anderson Professor of Cancer Treatment and Research, M.D. Anderson Cancer Center, Houston, TX 
RELEVANT PUBLICATIONS : (Selected from 247 publications) 
1 . 
2 . 
3. 
4. 
6 . 
7. 
Wedrychowski A, Howard OMZ, Seong D, Paslidis N, Talpaz M, Kantaijian H, Hester J, Turpin J, Lopez-Berestein G, 
Gutterman J, Freireich E, and Deisseroth A: Alpha-interferon alters binding of 84-, 50-, and 95-kDa nuclear proteins from CML 
patients to interferon-inducible transcriptional enhancers. J Biol Chem 265:21433-21440, 1990. 
Seong DC, Sims S, Johnson E, Howard OMZ, Hester J, Talpaz M, Kantaijian H, and Deisseroth A: A phosphatase activity 
present in peripheral blood myeloid cells of CML patients but not normal individuals alters nuclear protein binding to 
transcriptional enhancers of interferon-inducible genes. J Clin Invest 86:1664-1670, 1990. 
Wallerstein R Jr, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, LeMaistre 
CF, Dicke K, and Deisseroth A: A phase II study of mitoxantrone, etoposide (VP-16), and thiotepa (MVT) with autologous 
marrow support for patients with relapsed breast cancer. J Clin Oncol 8:1-4, 1990. 
Estey EH, Dixon D, Kantaijian H, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, 
and Gutterman JU: Treatment of poor-prognosis, newly-diagnosed acute myeloid leukemia with Ara-C and recombinant human 
granulocyte-macrophage colony-stimulating factor. Blood 75:1766-1769. 1990. 
Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talfiaz M, Kantaijian H, Lopez-Berestein G, Reading C, and 
Deisseroth A: Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C- 
dependent pathway in CML cell lines. Br J Haematol 78:359-367, 1991. 
Claxton D, Suh S-P, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, Belmont 
J, Moore K, Talpaz M, Kantaijian H, and Deisseroth A: Molecular analysis of retroviral transduction in chronic myelogenous 
leukemia. Human Gene Therapy 2:317-321, 1991. 
Etkin M, Filaccio M, Ellerson D, Suh S-P, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Mosely AM, 
Reading C, Khouri I, Talpaz M, Kantaijian H, and Deisseroth A: Use of cell-free supernatants of safety-modified viruses for 
transduction of cells from the marrow of chronic phase and blast crisis CML patients and from normal individuals. Human Gene 
Therapy 3:137-145, 1992. 
Recombinant DNA Research, Volume 19 
[543] 
